Breaking News for Aug. 9, 2004
Best Practices for Proactively Preventing PBM Audit Issues | NCPA 2024
Trent Thiede, PharmD, MBA, president of PAAS National, discusses best practices that pharmacy teams can implement to proactively prevent audit issues before they arise.
Keeping the Focus on Community Pharmacy Advocacy at the State Level
Drug Topics discussed independent pharmacy advocacy and PBM reform on the state level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.
Guselkumab’s Promising Results as First Subcutaneous IL-23 Inhibitor to Treat Crohn’s
Johnson & Johnson announced results from its phase 3 GRAVITI trial exploring guselkumab’s results in subcutaneous (SC) induction and maintenance therapy for treating Crohn’s disease.
How Pharmacy Advocacy is Heating Up at the Federal Level
Drug Topics discussed independent pharmacy advocacy and PBM reform on the federal level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.
FDA Approves Abuse-Deterrent 10 mg Oxycodone Hydrochloride for Severe Pain
The addition of a 10 mg oxycodone hydrochloride tablet improves dosing flexibility and precision.
Importance of NCPA’s Annual Conference to the Independent Pharmacy Community | NCPA 2024
At the NCPA 2024 Annual Convention and Expo, Drug Topics asked different pharmacists what they think the importance of the conference is to the independent pharmacy community.
